Homocysteine as a non-classical risk factor for atherosclerosis in relation to pharmacotherapy of type 2 diabetes mellitus

• Authors: Magdalena Borowska , Marzena Dworacka , Hanna Winiarska , Ewa Krzyżagórska
• Languages of publication: EN

Abstracts

EN

Aims. The aim of our study was to evaluate which of the pharmacotherapeutic methods that are frequently used to treat type 2 diabetes is associated with the most beneficial profile in relation to pro-atherogenic homocysteine levels. Patients and Methods. We measured the serum homocysteine level in 182 patients with type 2 diabetes treated with metformin (89), treated with insulin in combination with metformin (31), receiving sulfonylureas (31) and treated conventionally with insulin (31). The total homocysteine levels in the serum were assayed. To exclude the influence of selected metabolic and anthropometric factors on the differences between the examined groups, multivariate analysis of covariance was used (ANCOVA). In this analysis, serum homocysteine concentration was the dependent variable, while diabetes duration, waist circumference, HbA1c, 1,5-anhydro-D-glucitol, fasting glycaemia and peptide C were used as covariates. Results. The serum homocysteine levels in patients treated with insulin in monotherapy were significantly higher than what was observed in the metformin treated subjects and in the patients receiving insulin combined with metformin. The analysis of covariance also confirmed that the differences between the therapeutic groups were affected by waist circumference and the C-peptide levels. Conclusion. We conclude that conventional insulin therapy may have a negative effect on pro-atherogenic homocysteine levels in patients with type 2 diabetes. This study revealed that pro-atherogenic homocysteine levels may not only be modified by pharmacotherapy of type 2 diabetes, but also by beta cell secretory function and abdominal obesity.

Keywords

EN

homocysteine; atherosclerosis; type 2 diabetes

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2017
• Volume: 64
• Issue: 4
• Pages: 603-607

Dates

published

2017

received

2016-12-07

revised

2017-07-11

accepted

2017-08-27

(unknown)

2017-12-07

Contributors

author

Magdalena Borowska

• Department of Pharmacology, University of Medical Sciences, Poznań, Poland

author

Marzena Dworacka

• Department of Pharmacology, University of Medical Sciences, Poznań, Poland

author

Hanna Winiarska

• Department of Pharmacology, University of Medical Sciences, Poznań, Poland

author

Ewa Krzyżagórska

• Poznan Specialist Center of Medical Care, Diabetology Outpatient Clinic, Poznań, Poland

References

• ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560-2572.
• American Diabetes Association (2007) Standards of medical care in diabetes - 2007. Diabetes Care 30: Suppl 1: S4–S41.
• Baszczuk A, Kopczynski Z (2014) Hyperhomocysteinemia in patients with cardiovascular disease. Postepy Hig Med Dosw (Online) 68: 579. doi: 10.5604/17322693.1102340.
• Bazzaz JT, Shojapoor M, Nazem H, Amiri P, Fakhrzadeh H, Heshmat R, Parvizi M, Ranjbar SH, Amoli MM (2010) Methylenetetrahydrofolate reductase gene polymorphism in diabetes and obesity. Mol Biol Rep 37: 105-109. doi: 10.1007/s11033-009-9545-z.
• Becker A, Smulders YM, van Guldener C (2003) Epidemiology of homocysteine as a risk factor in diabetes. Metab Syndr Relat Disord 1: 105-120. doi: 10.1089/154041903322294434.
• Björck J, Hellgren M, Råstam L, Lindblad U (2006) Associations between serum insulin and homocysteine in a Swedish population - a potential link between the metabolic syndrome and hyperhomocysteinemia: The Skaraborg project. Metab Clin Exp 55: 1007–1013. doi: 10.1016/j.metabol.2006.03.010.
• Chakraborty A, Chakraborty A, Chowdhury S, Sengupta S, Bhattacharyya M (2015) Association of MTHFR 677C>T genetic polymorphism with hyperhomocysteinemia in type 2 diabetes patients. Cogent Medicine 2: 1017973
• Chehadeh SW, Jelinek HF, Al Mahmeed WA, Tay Guan K, Odama UO, Elghazali GE, Al Safar HS (2016) Relationship between MTHFR C677T and A1298C gene polymorphisms and complications of type 2 diabetes mellitus in an Emirati population. Meta Gene 9: 70-75.
• Dierkes J, Westphal S (2005) Effect of drugs on homocysteine concentrations. Semin Vasc Med 5: 124-139. doi: 10.1055/s-2005-872398.
• Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek M, Henderson WG, Huang GD, MPH (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360: 129-139. doi: 10.1056/NEJMoa0808431.
• Dworacka M, Winiarska H (2005) The application of plasma 1.5-anhydro-D-glucitol for monitoring type 2 diabetic patients. Dis Markers 21: 127-132.
• European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88-136.
• Fekih-Mrissa N, Mrad M, Ibrahim H, Akremi I, Sayeh A, Jaidane A, Ouertani H, Zidi B, Gritli N (2017) Methylenetetrahydrofolate reductase (MTHFR) (C677T and A1298C) polymorphisms and vascular complications in patients with type 2 diabetes. Can J Diabetes 41: 366-371. doi: 10.1016/j.jcjd.2016.11.007.
• Gallistl S, Sudi K, Mangge H, Erwa W, Borkenstein M (2000) Insulin is an independent correlate of plasma homocysteine levels in obese children and adolescents. Diabetes Care 23: 1348-1352.
• Gurda D, Handschuh L, Kotkowiak W, Jakubowski H (2015) Homocysteine thiolactone and N-homocysteinylated protein induce pro-atherogenic changes in gene expression in human vascular endothelial cells. Amino Acids 47: 1319-1339. doi: 10.1007/s00726-015-1956-7.
• Guthikonda S, Haynes WG (2006) Homocysteine: role and implications in atherosclerosis. Curr Atheroscler Rep 8: 100-106.
• Jacobs RL, House JD, Brosnan ME, Brosnan JT (1998) Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat. Diabetes 47: 1967-1970.
• Jager J, Kooy A, Lehert P, Wulffelé MG, van der Kolk J, Bets D, Verburg J, Donker AJ, Stehouwer CD (2010) Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 340: c2181. doi: 10.1136/bmj.c2181.
• Mohammadi M, Amini M, Aminiorroay A, Rezvanian H, Kachuei A, Siyavash M, Saghand SR, Afkhami-Ardekani M (2009) Effect of metformin and folic acid on plasma homocysteine level in type 2 diabetic patients. Int J Med Med Sci 3: 88-90
• Mojtabai R (2004) Body mass index and serum folate in childbearing age women. Eur J Epidemiol 19: 1029-1036.
• Nakazato M, Maeda T, Takamura N, Wada M, Yamasaki H, Johnston KE, Tamura T (2011) Relation of body mass index to blood et al. (2011) Relation of body mass index to blood folate and total homocysteine concentrations in Japanese adults. Eur J Nutr 50: 581-585.
• Pushpakumar S, Kundu S, Sen U (2014) Endothelial dysfunction: the link between homocysteine and hydrogen sulfide. Curr Med Chem 21: 3662-3672.
• Ratnam S, Maclean KN, Jacobs RL, Brosnan ME, Kraus JP, Brosnan JT (2002) Hormonal regulation of cystathionine beta-synthase expression in liver. J Biol Chem 277: 42912-42918. doi: 10.1016/S2215-0366(14)00081-9.
• Refsum H, Smith AD, Ueland M, Nexo E, Clarke R, McPartlin J, Johnston C, Engbaek F, Schneede J, McPartlin C, Scott JM (2004) Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 50: 3-32. doi: 10.1373/clinchem.2003.021634.
• Sato Y, Ouchi K, Funase Y, Yamauchi K, Aizawa T (2013) Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes. Endocr J 60: 1275-1280.
• Seo H, Oh H, Park H, Park M, Jang Y, Lee M (2010) Contribution of dietary intakes of antioxidants to homocysteine-induced low density lipoprotein (LDL) oxidation in atherosclerotic patients. Yonsei Med J 51: 526-533. doi: 10.3349/ymj.2010.51.4.526.
• Signorello MG, Segantin A, Passalacqua M, Leoncini G (2009) Homocysteine decreases platelet NO level via protein kinase C activation. Nitric Oxide 20: 104-113. doi: 10.1016/j.niox.2008.11.005.
• U.K. Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853.
• Valdés-Ramos R, Guadarrama-López AL, Martínez-Carrillo BE, Benítez-Arciniega AD (2015) Vitamins and type 2 diabetes mellitus. Endocr Metab Immune Disord Drug Targets 15: 54-63.
• Vayá A, Rivera L, Hernández-Mijares A, de la Fuente M, Solá E, Romagnoli M, Alis R, Laiz B (2012) Homocysteine levels in morbidly obese patients: its association with waist circumference and insulin resistance. Clin Hemorheol Microcirc 52: 49-56. doi: 10.3233/CH-2012-1544.
• Wile DJ, Toth C (2010) Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 33: 156-161. doi: 10.2337/dc09-0606.
• Yabuuchi M, Masuda M (1984) Simple enzymatic method for determining 1,5-anhydro-D-glucitol for diagnosis of diabetes mellitus. Clin Chem 35: 2039-2043.

Identifiers

DOI

10.18388/abp.2016_1489